Trial Profile
CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Nomacopan (Primary)
- Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONSERVE
- Sponsors Akari Therapeutics
- 11 Dec 2020 According to a Akari Therapeutics media release, full clinical details on all 19 PNH patients treated with nomacopan will be provided in a manuscript that is currently in preparation.
- 11 Dec 2020 Results (n=19) derived from COBALT, CAPSTONE and long-term safety study CONSERVE presented in an Akari Therapeutics Media Release.
- 05 Oct 2020 Status changed from recruiting to discontinued.